拔管后无创通气间歇期使用高流量鼻导管氧疗:一项观察性研究
该观察性研究基于两项多中心临床试验,纳入1077例拔管后接受预防性NIV的高危患者(>65岁或合并基础心/肺疾病),比较NIV间歇期使用HFNC(NIV/HFNC,n=655)与标准氧疗(NIV/O2,n=422)。未调整分析显示第7天拔管失败率NIV/HFNC组显著低于NIV/O2组(13.7% vs 18.5%,差异-4.7%,95%CI -9.4%至-0.3%,p=0.036),但G-computation调整后差异为-3.9%(95%CI -8.7%至0.9%),未达显著。48h再插管率NIV/HFNC组显著更低,48h后无显著差异。结论认为HFNC可能降低拔管失败风险,需未来临床试验验证。
要点
- 高危拔管患者(>65岁或合并基础心/肺疾病)预防性NIV间歇期,HFNC组第7天拔管失败率13.7%,标准氧疗组18.5%,未调整差异-4.7%(95%CI -9.4%至-0.3%,p=0.036)。
- 经G-computation调整混杂后,HFNC较标准氧疗的拔管失败风险差异为-3.9%(95%CI -8.7%至0.9%),未达统计学显著。
- 48h再插管率HFNC组显著低于标准氧疗组,但48h后两组再插管率无显著差异。
- 该研究为观察性设计,基于两项多中心临床试验数据,HFNC对拔管失败的保护作用需未来RCT验证。
适用人群与场景
- 拔管后接受预防性NIV的高危患者,高危定义为>65岁或合并基础心脏或呼吸系统疾病。
- 数据来源于两项多中心临床试验,纳入1077例拔管后接受预防性NIV的患者。
诊断标准与关键阈值
- 拔管失败定义为拔管后7天内再插管或死亡。
- 高危拔管失败风险定义:>65岁或合并基础心脏或呼吸系统疾病。
处置流程与药物剂量
- 拔管后对高危患者给予预防性NIV,间歇期交替使用HFNC(NIV/HFNC)或标准氧疗(NIV/O2)。
- 原文未提及HFNC的具体流量、FiO2、NIV参数及交替频率等剂量或设置细节。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 观察性研究,基于两项多中心临床试验,纳入1077例拔管后预防性NIV的高危患者,NIV/HFNC组655例(61%),NIV/O2组422例(39%)。
- 主要终点第7天拔管失败率:NIV/HFNC组13.7% vs NIV/O2组18.5%,未调整差异-4.7%(95%CI -9.4%至-0.3%,p=0.036)。
- G-computation调整后估计差异为-3.9%(95%CI -8.7%至0.9%),未达统计学显著。
- 48h再插管率NIV/HFNC组显著低于NIV/O2组,48h后无显著差异。
证据类型、等级与局限
- 证据类型:观察性研究,基于两项多中心临床试验数据,采用G-computation进行因果推断调整混杂。
- 局限:观察性设计,调整后主要终点未达显著,原文结论认为HFNC可能降低拔管失败风险但需未来临床试验验证。
对床旁实践的改变
- 对>65岁或合并基础心/肺疾病的拔管后高危患者,预防性NIV间歇期可考虑使用HFNC而非标准氧疗,但现有证据为观察性且调整后未达显著,不能作为强推荐。
- 原文未提及HFNC的具体设置参数及适用/不适用人群的排除标准,临床使用时需结合个体情况。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Clinical practice guidelines recommend prophylactic noninvasive ventilation (NIV) after extubation in high-risk patients. The effects of high-flow nasal cannula (HFNC) oxygen during breaks from NIV after extubation have been poorly explored. Our objective was to assess whether HFNC rather than standard oxygen during breaks from NIV may prevent extubation failure.
METHODS: Observational study based on two multicenter clinical trials including patients at high-risk of extubation failure (> 65 years or with underlying cardiac or respiratory disease). We included the 1077 patients who received prophylactic NIV after extubation, alternating with HFNC (NIV/HFNC) or standard oxygen (NIV/O2). The primary outcome was the proportion of patients who failed extubation (reintubation or death within the seven days following extubation). We used G-computation to estimate the causal effect of HFNC on the risk of extubation failure, while accounting for confounding factors.
RESULTS: After extubation, 655 patients (61%) received NIV/HFNC while 422 (39%) received NIV/O2. The extubation failure rate at day 7 was significantly lower with NIV/HFNC than with NIV/O2 (13.7% vs. 18.5%; difference, - 4.7% [95% CI, - 9.4% to - 0.3%]; p = 0.036). Using G-computation, NIV/HFNC was not more effective than NIV/O2 in reducing the risk of extubation failure, with an estimated adjusted difference of - 3.9% [95% CI, - 8.7% to 0.9%]. Reintubation rates were significantly lower with NIV/HFNC than with NIV/O2 at 48h, but did not significantly differ beyond 48h.
CONCLUSIONS: Although the adjusted analysis did not confirm the favorable unadjusted findings, HFNC during breaks from NIV might decrease the risk of extubation failure, and warrants future clinical trials.
参考来源
- Thille AW, Chamblet L, Ragot S, et al. High-flow nasal cannula oxygen during breaks from noninvasive ventilation after extubation: an observational study. Intensive Care Med. 2026. PMID: 42440109. doi:10.1007/s00134-026-08544-w
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。